SUMMARY-The tumorigenic effect of two chemical carcinogens, 7,12-dimethylbenz[alanthracene (DMBA) and urethan, and of 'Y-irradiation were analyxed further on the nodule outgrowth line D1. Nodule outgrowth line D1 treated with DMBA and urethan produced 68 and 83% tumors, respectively, whereas irradiated outgrowths produced only 23%. Prolonged hormone stimulation by a single pituitary isograft enhanced the tumorigenic effect of DMBA, had no effect on urethan-induced tumorigenesis, and inhibited irradiation-induced tumorigenesis. Nodule outgrowths were exposed to various doses of DMBA and urethan. Outgrowths exposed to 1.0 mg and 1.5 mg DMBA produced the same tumor incidence (68%), whereas outgrowths exposed to 0.5 mg produced only 50% tumors. The various doses of urethan produced mammary tumors in the following order: 200 mg >100 mg = 80 mg >60 mg = 40 mg >20 mg. The time of administration of urethan was important in determination of the ultimate tumor incidence and the rate of tumor formation. Outgrowths exposed to urethan between 3 and 5 weeks after transplantation produced tumors earlier and at a higher incidence than outgrowths exposed to urethan at later periods. 
9lO
MEDINA thracene (DMBA), and urethan, and 'Y-irradiation increased the tumor-producing capabilities of outgrowth line D 1 to 50, 64, 76, and 22%, respectively (2,3). 3) Prolonged hormone stimulation by pituitary isografts did not significantly increase the tumor-producing capabilities of line Dl (4). However, it did potentiate the effect of MCAinduced tumorigenesis in Dl outgrowths (2) . The purpose of the present studies was to extend these observations on carcinogen-treated nodule outgrowths to determine the following: 1) Does prolonged hormone stimulation potentiate the tumorigenic effect ofDMBA, urethan, and irradiation? 2) What doses of DMBA and urethan are most effective in producing mammary tumors? 3) Is the tumorigenic response of outgrowth line D 1 to urethan influenced by its degree of proliferation, as has been suggested for liver (5-7), skin (8, 9) , in vitro carcinogenesis (10) , and MCA-induced mammary gland tumorigenesis (11)?
MATERIALS AND METHODS
Animals.-BALB/c mice, free of detectable MTV and its variant NIV (3, 12) , were used in all experiments. A1l mice were obtained from the Cancer Research Genetics Laboratory colony, University of California, Berkeley, housed 6-10 to a cage in temperature-controlled and light-cyc1e-controlled rooms, fed Purina Breeder Chow or Berkeley Diet (1) , and given water ad libitum.
Transplantation.-The hyperplastic nodule outgrowth line D 1 was used in all experiments. The origin and tumor-producing capabilities of outgrowth line Dl have been previously reported (1) (2) (3) (4) 12) . Samples of the nodule outgrowths were transplanted into the inguinal mammary glandfree fat pads of 3-week-old BALB/c female mice by the standard method of DeOme et al. (13) . All mice were palpated once weekly for mammary tumors. Tumors were removed from mice when they were first palpable, fixed in Tellyesniczky's solution, embedded in paraffin, sectioned at 7 p., and stained with hematoxylin and eosin.
The procedures for prolonged hormone stimulation of the host's mammary glands and of the nodule outgrowths were previously reported (2) . Similarly, the conditions for administration of the chemical carcinogens and 'Y-irradiation· were previously reported (3) . Mice received DMBA between 5 and 7 weeks after transplantation of the outgrowths and urethan between 3 and 14 weeks after transplantation of the outgrowths.
Experiments.-In experiment 1, the effects of different doses of DMBA on the tumor potential of Dl outgrowths were investigated. The mice were divided into 6 groups. Outgrowths were transplanted into both inguinal fat pads of 3-weekold mice in all groups except group 5, which received a single transplant in the right inguinal fat pad only. A single male pituitary gland was transplanted under the kidney capsule in mice of group 6 when the mice were 4 weeks old and remained in place permanently. The DMBA (0.5 mg) was fed to mice in the various groups at the times indicated in table 1. figure 1 .
In experiment 3, D I outgrowths were transplanted into: a) unstimulated and hormonestimulated unirradiated mice; b) unstimulated and hormone-stimulated mice irradiated 7 weeks after transplantation; and c) unstimulated and hormonestimulated mice irradiated 16 weeks after transplantation. A single dose of whole-body irradiation (450 R, 11.4 R/min) was administered. The results are shown in table 3.
Two types of nonparametric statistical tests, the Mann-Whitney U test and the Median test, were used for these data. The 50% tumor endpoint was defined as the time it took 50% of the nodule transplants to produce tumors (4) .
RESULTS

Effect of OMBA on Tumor-Producing Capabilities of 01 Outgrowths
The results are shown in table 1. D I outgrowth maintained in untreated mice produced only 4% tumors (1/24, group I). DI outgrowths exposed to 0.5 mg DMBA produced 50% tumors (9/18, group 2) with the 50% tumor endpoint reached at 329 days. D1 outgrowths exposed to 1.0 mg DMBA (group 3) and 1.5 mg DMBA (group 4) produced 65% tumors (15/23) and 68% tumors (34/50), respectively, with the 50% tumor endpoints attained at 259 and 244 days, respectively.
The tumor distributions of outgrowths exposed to 1.0 mg or 1.5 mg DMBA were not significantly different from each other, though they were significantly different from groups 1 and 2 (P<O.05).
The tumor incidence and distribution of outgrowths in group 5 were compared with group 4 to determine whether two outgrowths in the same host might be treated independently as to tumor development. The results in group 5 were not significantly different from those in group 4. Tumor TEXT-FIGURE I.-Effect of dose of urethan (mg) given at varying weekly intervals on the tumor-producing capabilities ofDI nodule outgrowths. This histogram combines the results of hormone-stimulated and unstimulated outgrowths for any given group. Group I represents mice given urethan weekly between 5 and 14 weeks after transplantation of the outgrowths; group II, mice given urethan at 5,7,9, II, and 13 weeks; group III, mice given urethan at 5,7,9, and 11 weeks; group IV, urethan given at 3, 4, and 5 weeks; group V, urethan given at 7, 8, and 9 weeks; group VI, urethan given at 3 and 5 and 4 and 5 weeks; group VII, urethan given at 5 and 9 and 7 and 9 weeks; group VIII, urethan given at 4, 5, 7, or 9 weeks. 6). An analysis of the tumor distribution of hormone-stimulated, DMBAtreated outgrowths revealed that most of the tumors were produced within 3 weeks, and though hormone stimulation delayed the initial time of tumor formation, it narrowed the range of tumor appearance.
Effect of Urethan on Tumor-Producing Capabilities of 01 Outgrowths
The data are summarized in table 2. DI outgrowths exposed to urethan alone produced 40.7% tumors (99/243) with a mean latent period of 254 days, whereas outgrowths exposed to urethan and hormone stimulation produced 39.9% tumors (99/248) with a mean latent period of 248 days. These results were not statistically different (P>0.05).
Since the results indicated hormone stimulation had no significant effect on urethan-induced tumorigenesis, the tumor incidences of the groups of mice treated with urethan at different times were calculated by combination of the number of mice exposed to urethan and urethan plus hormone stimulation for any particular group. The data are presented in text-figure I. D I outgrowths exposed tumors (28/130), outgrowths exposed to 40 mg (groups VI and VII) or 60 mg (groups IV and V) urethan produced 37% tumors (67/179, 26/67, respectively), outgrowths exposed to 80 mg urethan (group III) produced 68% tumors (23/34), outgrowths exposed to 100 mg urethan (group II) produced 73% tumors (40/55), and outgrowths exposed to 200 mg urethan (group I) produced 78% tumors (73/93). Thus the tumor incidence increased with increasing doses of urethan. However, the time of urethan administration also determined tumor incidence. Outgrowths exposed to 20 mg urethan each at 3 and 5 weeks or 4 and 5 weeks (group VI) produced 56% tumors (40/71), whereas outgrowths exposed to 20 mg urethan each at 5 and 9, 5 and 7, or 7 and 9 weeks (group VII) produced only 25% tumors (27/108). This effect was seen with a total of 60 mg urethan, whereas outgrowths exposed to 20 mg urethan each at 3, 4, and 5 weeks (group IV) produced 53% tumors (19/37), and outgrowths exposed to 20 mg urethan each at 7, 8, and 9 weeks (group V) produced only 21 % tumors (7/30). These results dearly indicate that DI outgrowths treated with urethan soon after transplantation produced more tumors than outgrowths treated later.
The rate of tumor formation was greater in outgrowths exposed to 200 mg urethan than in those exposed to 80 or 100 mg urethan. D I outgrowths exposed to 80 and 100 mg reached the 50% tumor endpoint at 294 days and 288 days, respectively, whereas outgrowths exposed to 200 mg reached the 50% tumor endpoint at 224 days.
Effect of Irradiation on T umor-Produeing Capabilities of 01 Outgrowths
The results are shown in table 3. DI outgrowths in unirradiated, unstimulated mice (group I) failed to produce tumors (0/16) by 338 days. Dl outgrowths in unirradiated, hormone-stimulated mice (group 2) produced 11 % tumors (2/18) with a mean latent period of 354 days. Dl outgrowths in unstimulated mice, irradiated 7 weeks after transplantation (group 3), produced 24% tumors (8/33) with a mean latent period of 234 days, whereas outgrowths in hormone-stimulated mice, irradiated 7 weeks after transplantation (group 4), produced only 9% tumors (3/34) with a mean latent period of 217 days.
DI outgrowths in unstimulated mice, irradiated 16 
DISCUSSION
The data reported herein provide additional evidence that the tumor potential of preneoplastic nodule outgrowth cell populations can be increased by exposure to several different chemical carcinogens and 'Y-irradiation (3). DMBA, urethan, and 'Y-irradiation increased the tumor potential of D I outgrowths from 4-68, 83, and 23%, respectively. The poor tumorigenic response from irradiation might be attributed to the permanent atrophy of primordial and graaffian follicles induced by irradiation and gradual loss of corpora lutea (14) . The histological changes in urethan and DMBAtreated adult BALB/c mouse ovaries are not well documented, though DMBA does induce granulosa cell tumors in BALB/c mice (15) .
The effect of various dosages of the various oncogenic agents used were measured on DI nodule outgrowths. DMBA and urethan showed a definite correlation between dose and tumor incidence. Dl VOL. 46, NO.4, APRll.. 1971
416-3iOl~71--25 outgrowths exposed to 1.0 mg DMBA produced as many tumors as outgrowths exposed to 1.5 mg DMBA; however, 0.5 mg DMBA was definitely not as effective as the 2 higher doses (table I ).
U rethan was tested over a larger dose range, 20-200 mg. Outgrowths exposed to 200 mg urethan produced a similar high tumor incidence but a shorter tumor latent period than outgrowths exposed to 100 and 80 mg. Outgrowths exposed to 40 and 60 mg were equally effective, but produced fewer tumors than the higher doses. Outgrowths exposed to 20 mg produced only 20% tumors.
The time of administration also determined the response of outgrowths to the carcinogens. This factor was clearly shown in the urethan experiments (text- fig.l ). DI outgrowths exposed to mg of urethan between 3 and 5 weeks after transplantation had a much higher incidence of tumors than Dl outgrowths exposed to urethan at later periods. This correlates with the finding that Dl outgrowths exposed to 1.0 mg MCA between 3 and 5 weeks after transplantation produced a higher incidence of tumors than outgrowths exposed to MeA between 9 and 12 weeks after transplantation (11) .
There are two alternative explanations which might account for the different responses of outgrowths to carcinogens administered at different times. Either the nodule outgrowths were more responsive to carcinogens shortly after transplantation, or the metabolism of the carcinogen varied with the age of the host. There is considerable information regarding the metabolism of urethan in infant and adult mice. This area was recently reviewed by Mirvish (16) . Although there is a difference in urethan metabolism between infant and adult mice (17, 18) , the adult rate of elimination occurs in mice 3 weeks before the earliest time urethan was administered to mice in the experiments reported herein. In previous experiments, any nonspecific effects of host age that might influence the response of the transplanted outgrowths to MCA were controlled, and no such effects were evident (11) .
Apparently, the first explanation is the correct one; i.e., the nature of the cell population exposed to the carcinogen determined the response of the outgrowths. Several authors believe that actively dividing cells are more susceptible to carcinogens than nondividing cells. Shinozuka and Ritchie (9) demonstrated that the yield of papillomas induced by a single application of DMBA or urethan followed by repeated applications of croton oil was increased when croton oil also was given 24 hours before, but not 72 hours before, the administration of the carcinogen. They suggested that the carcinogen was exerting its influence on epidermal cells synthesizing DNA. An analogous situation occurs in urethaninduced liver cancer. Lane et at. (5) suggested that the increased rate of proliferation of liver cells after partial hepatectomy enhanced the susceptibility of the liver to the carcinogenic action of urethan. Similarly, Hollander and Bentvelzen (6) concluded that rapid liver proliferation after partial hepatectomy enhanced urethan carcinogenesis in the mouse liver. Sachs and co-workers have also stressed the importance of cell division in in vitro chemical and irradiation carcinogenesis (10) .
Their results indicate that the expression of chemically transformed cells requires a process associated with cell division (19) .
The in vivo and in vitro experiments discussed above are relevant to these results. It is known that the maximum rate of proliferation of Dl outgrowths occurs between 3 and 5 weeks after transplantation (11) , and Dl outgrowths respond maximally to MCA at the time of rapid cell division (J 1). The experiments reported herein suggest that D 1 outgrowths respond maximally to urethan at the time of rapid cell division. In addition, the lesser response of the outgrowths treated after 5 weeks could be overcome by increasing the dose of urethan (text- fig. 1 ). Similar results were found by Vesselinovitch and Mihailovitch (20) , who found that the leukemogenic response of 7-day-old mice could be increased to that of newborn mice by increasing the dose of urethan. D 1 outgrowths exposed to irradiation at 7 weeks (group 3) and 16 weeks (group 5) after transplantation did not show different tumor responses (table 3) . The percentage of actively dividing cells is probably not significantly different between the 2 groups (J 1, 21); thus a differential effect of irradiation was not evident.
The number of cells per se in a nodule cell population was not a contributing factor in determination of the tumor response to any particular carcinogen. Dl outgrowths exposed to urethan at 7 and 9 weeks had roughly 75-100% more cells than outgrowths exposed to urethan at 3 and 5 weeks (11) . Similarly, Dl outgrowths exposed to irradiation at 16 weeks (100% of the fat pad filled with outgrowth) had 50% more cells than outgrowths exposed to irradiation at 7 weeks (11) .
Chemical carcinogenesis of the mammary gland in BALB/c mice depends on hormonal stimulation of the gland. Biancifiori et at. (15, 22) showed that pseudopregnancy increased to 44% the incidence of mammary tumors in MCA-treated BALB/c mice, while virgin BALB/c mice treated with MCA produced only 11 % tumors. Haran-Ghera (23) induced tumors in LAF mice treated with urethan or MCA; however, the concomitant presence of hormone stimulation by pituitary isografts was necessary for a high incidence of mammary tumors.
Faulkin (24) reported the induction of hyperplastic alveolar nodules in BALB/c mice by MCA; however, prolonged hormone stimulation was necessary for nodule development. He has recently shown the same dependency on hormone stimulation for the early appearance of nodules after treatment with DMBA, urethan, or X irradiation (Faulkin, personal communication).
The results reported here indicate that prolonged hormone stimulation is not necessary for the formation of mammary tumors from carcinogentreated preneoplastic nodule cell populations. Hormone stimulation exerts a synergistic effect on DMBA-induced DI tumorigenesis as it does on MeA-induced Dl tumorigenesis (2). However, hormone stimulation had no effect on urethaninduced DI tumorigenesis and inhibited irradiation-induced DI tumorigenesis.
The effectiveness of chemical carcinogens without prolonged hormone stimulation for the induction of the neoplastic transformations compared to the nodule transformation might be due to several conditions:
1) The effects seen may be quantitative; i.e., a fat pad containing nodule outgrowths contains more parenchyma cells than a fat pad containing normal ductal cells. However, the previously discussed experiments indicated cell number per se was not an important determining factor.
2) Hormone stimulation, as in pregnancy, leads to an increase in the proliferating cell population which is more susceptible to chemical or physical carcinogens. The previously discussed experiments stress the importance of cell division for chemical carcinogenesis; thus this factor could be important for noduligenesis. However, the critical experiment of comparison of mitotic rate in a normal ductal cell population undergoing alveolar differentiation to its susceptibility to chemical carcinogenesis has not been done. 3) Finally, continuous hormone stimulation leads to the development of alveoli which may be the cells at risk for chemical carcinogenesis.
If alveoli are the cells at risk, it would explain the importance of hormone stimulation of the mammary gland for noduligenesis, and might explain the response of nodule outgrowth lines to chemical carcinogens without prolonged hormonal stimulation, since nodule outgrowth lines retain their alveolar morphology in the hormonal milieu of a nonpregnant mouse. Apparently, carcinogen-induced neoplastic transformation is related both to the presence of alveolar cells and to the extent of cell division in the alveolar cell population.
